Matinas BioPharma Announces the Termination of MAT2203 Partnership Negotiations and Implements Immediate Workforce Reduction
Matinas Biopharma Holdings, Inc. (MTNB)
NASDAQ:AMEX Investor Relations:
ir.matinasbiopharma.com
Company Research
Source: GlobeNewswire
BEDMINSTER, N.J., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB) announces that negotiations under the previously disclosed non-binding term sheet regarding global rights to MAT2203, its oral formulation of amphotericin B, have been terminated following notification from the prospective partner. As a result, Matinas has implemented an 80% workforce reduction effective immediately, eliminating 15 positions including three members of senior management, and has ceased all product development activities to conserve cash. The departing senior executives include Chief Medical Officer Dr. James Ferguson, Chief Business Officer Thomas Hoover and Chief Technology Officer Dr. Hui Liu. The Board intends to retain an advisor to assist the Company with the potential asset sale of MAT2203, its lead Phase 3-ready antifungal drug candidate for the treatment of invasive fungal infections, and will evaluate other alternatives, including but not limited to w
Show less
Read more
Impact Snapshot
Event Time:
MTNB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MTNB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MTNB alerts
High impacting Matinas Biopharma Holdings, Inc. news events
Weekly update
A roundup of the hottest topics
MTNB
News
- Matinas Biopharma Holdings, Inc. (NYSE: MTNB) was downgraded by analysts at Alliance Global Partners from a "strong-buy" rating to a "hold" rating.MarketBeat
- Matinas Biopharma Holdings, Inc. (NYSE: MTNB) was downgraded by analysts at Maxim Group from a "strong-buy" rating to a "hold" rating.MarketBeat
- Matinas Biopharma Holdings, Inc. (NYSE: MTNB) was downgraded by analysts at Alliance Global Partners from a "strong-buy" rating to a "hold" rating.MarketBeat
- Matinas Biopharma Holdings, Inc. (NYSE: MTNB) was downgraded by analysts at Maxim Group from a "strong-buy" rating to a "hold" rating.MarketBeat
MTNB
Sec Filings
- 11/27/24 - Form 8-K
- 11/13/24 - Form 10-Q
- 10/31/24 - Form 8-K
- MTNB's page on the SEC website